Recruiting

Erector Spinae Plane Block with Morphine

Sponsor:

UCLA

Code:

NCT04849455

Conditions

Hepatic Resection

Acute Pain

Anesthesia

Anesthesia, Local

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

0.2% ropivacaine local anesthetic continuous erector spinae plane block

0.2% ropivacaine local anesthetic superficially taped continuous erector spinae plane block

Spinal Morphine

Study Details

Brief summary:

To determine whether the addition of erector spinae plane (ESP) catheters to existing multimodal analgesic regimen with intrathecal morphine provides superior postoperative analgesia in patients undergoing hepatic resection compared with patients not receiving ESP catheters.

Conditions

Hepatic Resection

Acute Pain

Anesthesia

Anesthesia, Local

Study ID

NCT04849455

Start date

May 24, 2021

Status verified date

Jun, 2022

Completion date

May 1, 2023

Anticipated

Primary completion date

May 1, 2023

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • undergoing hepatic resection
  • Admitting service requests APS consult
  • >18 years old and able to provide consent

Exclusion criteria:

  • pregnancy
  • incarceration
  • inability to communicate with the investigators and hospital staff
  • severe hepatic disease
  • chronic high-dose opioid use (defined as daily use for more than 4 weeks prior to surgery of at least the equivalent of 20 mg oxycodone);
  • BMI > 40 kg/m2
  • allergy to study medications (lidocaine, ropivacaine)

Study Design

Enrollment

70 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Active Treatment

This group will receive a continuous erector spinae block catheter followed by an infusion of ropivacaine 0.2% at 10ml automatic set bolus per 120 minutes with 2ml/hr continuous infusion (14mls total every 2 hours per catheter)

placebo comparator: Placebo

This group will receive a superficially placed (taped to the surface) erector spinae block catheter with a ropivacaine 0.2% infusion at 0.1ml /hr

Interventions

0.2% ropivacaine local anesthetic continuous erector spinae plane block

Treatment- continuous erector spinae block catheter followed by an infusion of ropivacaine 0.2% at 10ml automatic set bolus per 60 minute with 2ml/hr continuous infusion (12mls/hr total per catheter)

0.2% ropivacaine local anesthetic superficially taped continuous erector spinae plane block

Placebo- Superficially placed (taped to the surface) erector spinae block catheter with a ropivacaine 0.2% infusion at 0.1ml /hr

Spinal Morphine

200-300 mcg of spinal morphine

Primary outcome measure

  • Total opioid requirement postoperative day (POD) 1-3 [ Time Frame: Total use from post-operative day (POD) 1, as defined by 24 hours after intrathecal morphine, to POD 3 (3 days from admission to recovery unit) ]

Central Contacts and Locations

Central contacts

Engy T Said, MD

5597371904esaid@health.ucsd.edu

Locations

University of California, San Diego

Recruiting

San Diego, California, United States, 92103

More Information

Sponsor

University of California, San Diego

Last update posted

Jun 7, 2022

Last verified

Jun, 2022

Keywords

  • acute postoperative pain
  • erector spinae plane block
  • liver resection

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, San Diego on 2022-06-07.